These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22258320)

  • 21. Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients.
    del Pozo-Fernández C; Pardo-Ruiz C; Sánchez-Botella C; Blanes-Castañer V; López-Menchero R; Gisbert-Sellés C; Sánchez-Jodar C; Alvarez-Avellán L
    Nefrologia; 2012 May; 32(3):367-73. PubMed ID: 22592422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.
    Lazarus B; Wu A; Shin JI; Sang Y; Alexander GC; Secora A; Inker LA; Coresh J; Chang AR; Grams ME
    JAMA Intern Med; 2018 Jul; 178(7):903-910. PubMed ID: 29868840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lactate levels and risk of lactic acidosis with metformin in diabetic kidney disease patients.
    Bipi PK; George J; Gomathy S; Gracious N; Kumar S; Mohandas MK
    Saudi J Kidney Dis Transpl; 2017; 28(6):1356-1361. PubMed ID: 29265047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
    Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
    Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.
    Rajagopalan R; Iyer S; Perez A
    Diabetes Obes Metab; 2005 Mar; 7(2):161-9. PubMed ID: 15715889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
    Hsiao FY; Huang WF; Wen YW; Chen PF; Kuo KN; Tsai YW
    Drug Saf; 2009; 32(8):675-90. PubMed ID: 19591532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
    Hamann A; Garcia-Puig J; Paul G; Donaldson J; Stewart M
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
    Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes.
    Asche CV; McAdam-Marx C; Shane-McWhorter L; Sheng X; Plauschinat CA
    Diabetes Obes Metab; 2008 Aug; 10(8):638-45. PubMed ID: 17645555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes.
    Quilliam BJ; Ozbay AB; Sill BE; Kogut SJ
    Diabet Med; 2013 Nov; 30(11):1305-13. PubMed ID: 23586474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
    Komajda M; Curtis P; Hanefeld M; Beck-Nielsen H; Pocock SJ; Zambanini A; Jones NP; Gomis R; Home PD;
    Cardiovasc Diabetol; 2008 Apr; 7():10. PubMed ID: 18435852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin initiation and renal impairment: a cohort study in Denmark and the UK.
    Christiansen CF; Ehrenstein V; Heide-Jørgensen U; Skovbo S; Nørrelund H; Sørensen HT; Li L; Jick S
    BMJ Open; 2015 Sep; 5(9):e008531. PubMed ID: 26338686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Spontaneous Reporting Systems to Detect Host-Medication Interactions: Sex Differences in Oral Anti-Diabetic Drug-Associated Myocardial Infarction.
    Wang SH; Chen WJ; Hsu LY; Chien KL; Wu CS
    J Am Heart Assoc; 2018 Nov; 7(22):e008959. PubMed ID: 30571494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
    Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
    Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.